NCT07359703 A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle (Aurora-Blasto)
| NCT ID | NCT07359703 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Infertility Assisted Reproductive Technology |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,028 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,028 participants in total. It began in 2025-10-15 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In current treatments for In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), the creation of multiple embryos is a common practice. The decision to transfer an embryo is traditionally based on the morphological assessment by an embryologist, which, due to its nature, must be considered subjective. In certain regions, invasive embryo biopsy techniques, such as Preimplantation Genetic Testing for Aneuploidy (PGT-A), are used to detect chromosomal abnormalities and support decision-making regarding embryo transfer. However, there is a medical need to improve the outcomes of IVF/ICSI cycles through non-invasive and objective methods. As an academic center, our goal is to investigate promising innovative methods that, if successful, can be integrated into standard care. The aim of the Aurora blastocyst study is to evaluate the effectiveness of the Aurora test in selecting five-day-old embryos for fresh or frozen embryo transfer. Additionally, the study assesses whether the use of the Aurora test results in an increase in clinical pregnancy rates and live birth rates. The Aurora test is a non-invasive test for evaluating oocyte competence and subsequently the embryo obtained in an ICSI cycle (In Vitro Fertilization). This test is performed on cumulus cells (CC) surrounding the oocyte and uses mRNA expression profiles to evaluate the developmental potential of the oocytes. The test has been developed and validated for patients stimulated with human menopausal gonadotropins (HP-hMG), an ovulatory dose of hCG, and a single embryo transfer on day 3. The test will be performed by Fertiga nv, upon receiving patients cumulus cells. At our center, based on earlier research, the standard care involves a single embryo transfer on day 5. In this study, embryo selection based on morphology is compared with embryo selection based on morphology and the Aurora test. Finally, this study aims to evaluate the impact of the Aurora test score on the embryologist's selection decision for transferring a five-day-old embryo for single embryo transfer, by assessing parameters such as pregnancy rates and live birth rates.
Eligibility Criteria
Inclusion Criteria: 1. Patients undergoing ICSI treatment, with maximum 40 years of age at time of signing the ICF 2. Patients stimulated with GnRH antagonist/HP-hMG or GnRH antagonist/recFSH, scheduled for fresh SET Day 5 with hCG or dual trigger (hCG + GnRH agonist) or Patients stimulated with GnRH antagonist/HP-hMG or GnRH antagonist/recFSH, scheduled for delayed transfer of frozen/thawed SET Day 5 after a GnRH agonist trigger, hCG or dual trigger (hCG + GnRH agonist). 3. Patients undergoing a first, second, third or fourth ICSI cycle 4. Women with body mass index (BMI) higher than 17 and lower than 35 5. Women with regular cycles (between 24 and 35 days) 6. Non-and mild-smokers (\<10 cigarettes/day) 7. AMH 1,1 ng/ml (Bologna criteria), excluding poor responders according to Bologna criteria 8. Patients with fresh ejaculated semen or frozen donor semen Exclusion Criteria: 1. Patients with less than 8 follicles (≥12mm) on the day of their last echo visit before OPU. 2. Women with history of poor oocyte maturation in a previous cycle (\< 50% MII) 3. Women with Severe Endometriosis (≥ III AFS classification) (in the ovaries and if not surgically treated) 4. Patients scheduled for PGD (preimplantation genetic diagnosis of monogenic/single gene defects) and PGT-A (preimplantation genetic testing on aneuploidy) 5. Couples where the partner has an extremely low sperm count e.g.: severe oligo-astheno-teratozoospermia (OAT) with sperm count below 100.000/ml or TESE.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07359703 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Infertility Assisted Reproductive Technology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07359703 currently recruiting?
Yes, NCT07359703 is actively recruiting participants. Contact the research team at Dominic.Stoop@uzgent.be for enrollment information.
Where is the NCT07359703 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT07359703 clinical trial?
NCT07359703 is sponsored by University Hospital, Ghent. The trial plans to enroll 1,028 participants.